Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2017

04.08.2017 | Review

Breast cancer in Africa: prevalence, treatment options, herbal medicines, and socioeconomic determinants

verfasst von: Kiven Erique Lukong, Yetunde Ogunbolude, Jean Paul Kamdem

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer is the leading cause of cancer-related deaths in women worldwide. GLOBOCAN estimated about 1.7 million new cases of breast cancer diagnoses worldwide and about 522,000 deaths in 2012. The burden of breast cancer mortality lies in the developing low-income and middle-income countries, where about 70% of such deaths occur. The incidence of breast cancer is also rising in low-income and middle-income countries in Africa as trend towards urbanization, and adoption of Western lifestyles increases. In general, the triple-negative breast cancer (TNBC) subtype tends to be frequent in women of African ancestry. What are the factors contributing to this prevalence? Are there genetic predispositions to TNBC in African women? This review addresses these questions and provides an update on the incidence, survival, and mortality of breast cancer in Africans, with a focus on sub-Saharan Africans. We have also addressed factors that could account for ethical disparities in incidence and mortality. Further, we have highlighted challenges associated with access to essential drug and to healthcare treatment in some African countries and outlined alternative/herbal treatment methods that are increasingly implemented in Africa and other developing nations.
Literatur
1.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108PubMedCrossRef Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108PubMedCrossRef
2.
Zurück zum Zitat Torre LA, Siegel RL, Ward EM, Jemal A (2016) Global Cancer Incidence and Mortality Rates and Trends–An Update. Cancer Epidemiol Biomarkers Prev 25:16–27PubMedCrossRef Torre LA, Siegel RL, Ward EM, Jemal A (2016) Global Cancer Incidence and Mortality Rates and Trends–An Update. Cancer Epidemiol Biomarkers Prev 25:16–27PubMedCrossRef
3.
Zurück zum Zitat Ferlay J, Soerjmataram I, Ervik M, Dikshit R, Eser S, Mathers C (2013) GLOBOCAN 2012 cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, Lyon Ferlay J, Soerjmataram I, Ervik M, Dikshit R, Eser S, Mathers C (2013) GLOBOCAN 2012 cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, Lyon
4.
Zurück zum Zitat Aziz H, Hussain F, Sohn C, Mediavillo R, Saitta A, Hussain A, Brandys M, Homel P, Rotman M (1999) Early onset of breast carcinoma in African American women with poor prognostic factors. Am J Clin Oncol 22:436–440PubMedCrossRef Aziz H, Hussain F, Sohn C, Mediavillo R, Saitta A, Hussain A, Brandys M, Homel P, Rotman M (1999) Early onset of breast carcinoma in African American women with poor prognostic factors. Am J Clin Oncol 22:436–440PubMedCrossRef
5.
Zurück zum Zitat Abdulrahman GO Jr, Rahman GA (2012) Epidemiology of breast cancer in europe and Africa. J Cancer Epidemiol 2012:915610PubMedCrossRef Abdulrahman GO Jr, Rahman GA (2012) Epidemiology of breast cancer in europe and Africa. J Cancer Epidemiol 2012:915610PubMedCrossRef
6.
Zurück zum Zitat Brinton LA, Figueroa JD, Awuah B, Yarney J, Wiafe S, Wood SN, Ansong D, Nyarko K, Wiafe-Addai B, Clegg-Lamptey JN (2014) Breast cancer in Sub-Saharan Africa: opportunities for prevention. Breast Cancer Res Treat 144:467–478PubMedPubMedCentralCrossRef Brinton LA, Figueroa JD, Awuah B, Yarney J, Wiafe S, Wood SN, Ansong D, Nyarko K, Wiafe-Addai B, Clegg-Lamptey JN (2014) Breast cancer in Sub-Saharan Africa: opportunities for prevention. Breast Cancer Res Treat 144:467–478PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Ly M, Antoine M, Dembele AK, Levy P, Rodenas A, Toure BA, Badiaga Y, Dembele BK, Bagayogo DC, Diallo YL et al (2012) High incidence of triple-negative tumors in sub-saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital. Oncology 83:257–263PubMedCrossRef Ly M, Antoine M, Dembele AK, Levy P, Rodenas A, Toure BA, Badiaga Y, Dembele BK, Bagayogo DC, Diallo YL et al (2012) High incidence of triple-negative tumors in sub-saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako university hospital. Oncology 83:257–263PubMedCrossRef
8.
Zurück zum Zitat Donepudi MS, Kondapalli K, Amos SJ, Venkanteshan P (2014) Breast cancer statistics and markers. J Cancer Res Ther 10:506–511PubMed Donepudi MS, Kondapalli K, Amos SJ, Venkanteshan P (2014) Breast cancer statistics and markers. J Cancer Res Ther 10:506–511PubMed
9.
Zurück zum Zitat Dubey AK, Gupta U, Jain S (2015) Breast cancer statistics and prediction methodology: a systematic review and analysis. Asian Pac J Cancer Prev 16:4237–4245PubMedCrossRef Dubey AK, Gupta U, Jain S (2015) Breast cancer statistics and prediction methodology: a systematic review and analysis. Asian Pac J Cancer Prev 16:4237–4245PubMedCrossRef
10.
Zurück zum Zitat Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T et al (2008) Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 9:730–756PubMedCrossRef Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T et al (2008) Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 9:730–756PubMedCrossRef
11.
Zurück zum Zitat Kantelhardt EJ, Muluken G, Sefonias G, Wondimu A, Gebert HC, Unverzagt S, Addissie A (2015) A Review on Breast Cancer Care in Africa. Breast Care (Basel) 10:364–370CrossRef Kantelhardt EJ, Muluken G, Sefonias G, Wondimu A, Gebert HC, Unverzagt S, Addissie A (2015) A Review on Breast Cancer Care in Africa. Breast Care (Basel) 10:364–370CrossRef
13.
Zurück zum Zitat Chokunonga E, Borok MZ, Chirenje ZM, Nyakabau AM, Parkin DM (2013) Trends in the incidence of cancer in the Black population of Harare, Zimbabwe 1991-2010. Int J Cancer 133:721–729PubMedCrossRef Chokunonga E, Borok MZ, Chirenje ZM, Nyakabau AM, Parkin DM (2013) Trends in the incidence of cancer in the Black population of Harare, Zimbabwe 1991-2010. Int J Cancer 133:721–729PubMedCrossRef
14.
Zurück zum Zitat DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI, Jemal A (2016) Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin 66:290–308PubMedCrossRef DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI, Jemal A (2016) Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin 66:290–308PubMedCrossRef
15.
Zurück zum Zitat Boring CC, Squires TS, Health CW Jr (1992) Cancer statistics for African Americans. CA Cancer J Clin 42:7–17PubMedCrossRef Boring CC, Squires TS, Health CW Jr (1992) Cancer statistics for African Americans. CA Cancer J Clin 42:7–17PubMedCrossRef
16.
Zurück zum Zitat DeSantis C, Naishadham D, Jemal A (2013) Cancer statistics for African Americans, 2013. CA Cancer J Clin 63:151–166PubMedCrossRef DeSantis C, Naishadham D, Jemal A (2013) Cancer statistics for African Americans, 2013. CA Cancer J Clin 63:151–166PubMedCrossRef
17.
Zurück zum Zitat Ghafoor A, Jemal A, Cokkinides V, Cardinez C, Murray T, Samuels A, Thun MJ (2002) Cancer statistics for African Americans. CA Cancer J Clin 52:326–341PubMedCrossRef Ghafoor A, Jemal A, Cokkinides V, Cardinez C, Murray T, Samuels A, Thun MJ (2002) Cancer statistics for African Americans. CA Cancer J Clin 52:326–341PubMedCrossRef
18.
Zurück zum Zitat Wingo PA, Bolden S, Tong T, Parker SL, Martin LM, Heath CW Jr (1996) Cancer statistics for African Americans, 1996. CA Cancer J Clin 46:113–125PubMedCrossRef Wingo PA, Bolden S, Tong T, Parker SL, Martin LM, Heath CW Jr (1996) Cancer statistics for African Americans, 1996. CA Cancer J Clin 46:113–125PubMedCrossRef
19.
Zurück zum Zitat American-Cancer-Society (2016) Cancer facts and figures for African Americans, p 38 American-Cancer-Society (2016) Cancer facts and figures for African Americans, p 38
20.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. Journal international du cancer 136:E359–E386PubMedCrossRef Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. Journal international du cancer 136:E359–E386PubMedCrossRef
21.
Zurück zum Zitat Eng A, McCormack V, dos-Santos-Silva I (2014) Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis. PLoS Med 11:e1001720PubMedPubMedCentralCrossRef Eng A, McCormack V, dos-Santos-Silva I (2014) Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis. PLoS Med 11:e1001720PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Tetteh DA, Faulkner SL (2016) Sociocultural factors and breast cancer in sub-Saharan Africa: implications for diagnosis and management. Womens Health (Lond) 12:147–156CrossRef Tetteh DA, Faulkner SL (2016) Sociocultural factors and breast cancer in sub-Saharan Africa: implications for diagnosis and management. Womens Health (Lond) 12:147–156CrossRef
24.
Zurück zum Zitat World-Health-Organization (2012) WHO classification of tumours of the breast. International Agency for Research on Cancer (IARC), Lyon World-Health-Organization (2012) WHO classification of tumours of the breast. International Agency for Research on Cancer (IARC), Lyon
26.
Zurück zum Zitat Weigelt B, Reis-Filho JS (2009) Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 6:718–730PubMedCrossRef Weigelt B, Reis-Filho JS (2009) Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 6:718–730PubMedCrossRef
27.
Zurück zum Zitat Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef
28.
Zurück zum Zitat Prat A, Perou CM (2011) Deconstructing the molecular portraits of breast cancer. Mol Oncol 5:5–23PubMedCrossRef Prat A, Perou CM (2011) Deconstructing the molecular portraits of breast cancer. Mol Oncol 5:5–23PubMedCrossRef
29.
Zurück zum Zitat Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874PubMedPubMedCentralCrossRef Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Brenton JD, Carey LA, Ahmed AA, Caldas C (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 23:7350–7360CrossRef Brenton JD, Carey LA, Ahmed AA, Caldas C (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 23:7350–7360CrossRef
32.
Zurück zum Zitat Hon JD, Singh B, Sahin A, Du G, Wang J, Wang VY, Deng FM, Zhang DY, Monaco ME, Lee P (2016) Breast cancer molecular subtypes: from TNBC to QNBC. Am J Cancer Res 6:1864–1872PubMedPubMedCentral Hon JD, Singh B, Sahin A, Du G, Wang J, Wang VY, Deng FM, Zhang DY, Monaco ME, Lee P (2016) Breast cancer molecular subtypes: from TNBC to QNBC. Am J Cancer Res 6:1864–1872PubMedPubMedCentral
33.
Zurück zum Zitat Prat A, Karginova O, Parker JS, Fan C, He X, Bixby L, Harrell JC, Roman E, Adamo B, Troester M et al (2013) Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res Treat 142:237–255PubMedPubMedCentralCrossRef Prat A, Karginova O, Parker JS, Fan C, He X, Bixby L, Harrell JC, Roman E, Adamo B, Troester M et al (2013) Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res Treat 142:237–255PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750–2767PubMedPubMedCentralCrossRef Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750–2767PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434PubMedCrossRef Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434PubMedCrossRef
37.
Zurück zum Zitat Bird PA, Hill AG, Houssami N (2008) Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Ann Surg Oncol 15:1983–1988PubMedCrossRef Bird PA, Hill AG, Houssami N (2008) Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Ann Surg Oncol 15:1983–1988PubMedCrossRef
38.
Zurück zum Zitat Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O et al (2009) Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 27:4515–4521PubMedPubMedCentralCrossRef Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O et al (2009) Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 27:4515–4521PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Hubalek M, Czech T, Muller H (2017) Biological Subtypes of Triple-Negative Breast Cancer. Breast Care 12:8–14PubMedCrossRef Hubalek M, Czech T, Muller H (2017) Biological Subtypes of Triple-Negative Breast Cancer. Breast Care 12:8–14PubMedCrossRef
41.
Zurück zum Zitat Hahnen E, Hauke J, Engel C, Neidhardt G, Rhiem K, Schmutzler RK (2017) Germline Mutations in Triple-Negative Breast Cancer. Breast Care (Basel) 12:15–19CrossRef Hahnen E, Hauke J, Engel C, Neidhardt G, Rhiem K, Schmutzler RK (2017) Germline Mutations in Triple-Negative Breast Cancer. Breast Care (Basel) 12:15–19CrossRef
42.
Zurück zum Zitat Der EM, Gyasi RK, Tettey Y, Edusei L, Bayor MT, Jiagge E, Gyakobo M, Merajver SD, Newman LA (2015) Triple-Negative Breast Cancer in Ghanaian Women: the Korle Bu Teaching Hospital Experience. Breast J 21:627–633PubMedCrossRef Der EM, Gyasi RK, Tettey Y, Edusei L, Bayor MT, Jiagge E, Gyakobo M, Merajver SD, Newman LA (2015) Triple-Negative Breast Cancer in Ghanaian Women: the Korle Bu Teaching Hospital Experience. Breast J 21:627–633PubMedCrossRef
43.
Zurück zum Zitat Obomaa YI, Susana BE, Elesha SO, Jonathan M (2017) Breast cancer biomarkers at Niger delta university hospital: comparisons with national and international trends and clinical significance. Pathophysiology. doi:10.1016/j.pathophys.2017.05.002 Obomaa YI, Susana BE, Elesha SO, Jonathan M (2017) Breast cancer biomarkers at Niger delta university hospital: comparisons with national and international trends and clinical significance. Pathophysiology. doi:10.​1016/​j.​pathophys.​2017.​05.​002
44.
Zurück zum Zitat Rais G, Raissouni S, Aitelhaj M, Rais F, Naciri S, Khoyaali S, Abahssain H, Bensouda Y, Khannoussi B, Mrabti H et al (2012) Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology. BMC Womens Health 12:35PubMedPubMedCentralCrossRef Rais G, Raissouni S, Aitelhaj M, Rais F, Naciri S, Khoyaali S, Abahssain H, Bensouda Y, Khannoussi B, Mrabti H et al (2012) Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology. BMC Womens Health 12:35PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Campeau PM, Foulkes WD, Tischkowitz MD (2008) Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet 124:31–42PubMedCrossRef Campeau PM, Foulkes WD, Tischkowitz MD (2008) Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet 124:31–42PubMedCrossRef
46.
Zurück zum Zitat Pruss D, Morris B, Hughes E, Eggington JM, Esterling L, Robinson BS, van Kan A, Fernandes PH, Roa BB, Gutin A et al (2014) Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes. Breast Cancer Res Treat 147:119–132PubMedCrossRef Pruss D, Morris B, Hughes E, Eggington JM, Esterling L, Robinson BS, van Kan A, Fernandes PH, Roa BB, Gutin A et al (2014) Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes. Breast Cancer Res Treat 147:119–132PubMedCrossRef
48.
Zurück zum Zitat Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, Marchbanks PA, Simon MS, McDonald JA, Norman SA et al (2006) Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in White and Black American women ages 35 to 64 years. Cancer Res 66:8297–8308PubMedCrossRef Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, Marchbanks PA, Simon MS, McDonald JA, Norman SA et al (2006) Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in White and Black American women ages 35 to 64 years. Cancer Res 66:8297–8308PubMedCrossRef
49.
Zurück zum Zitat Antoniou AC, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Olsson H, Johannsson O, Borg A, Pasini B et al (2005) Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 42:602–603PubMedPubMedCentralCrossRef Antoniou AC, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Olsson H, Johannsson O, Borg A, Pasini B et al (2005) Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 42:602–603PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Nagy R, Sweet K, Eng C (2004) Highly penetrant hereditary cancer syndromes. Oncogene 23:6445–6470PubMedCrossRef Nagy R, Sweet K, Eng C (2004) Highly penetrant hereditary cancer syndromes. Oncogene 23:6445–6470PubMedCrossRef
51.
Zurück zum Zitat Lawal AO, Atoyebi O, Adesunkanmi AK (2012) Seventeen years after BRCA1: what is the BRCA mutation status of the breast cancer patients in Africa? A systematic review. Springerplus. doi:10.1186/2193-1801-1-83 Lawal AO, Atoyebi O, Adesunkanmi AK (2012) Seventeen years after BRCA1: what is the BRCA mutation status of the breast cancer patients in Africa? A systematic review. Springerplus. doi:10.​1186/​2193-1801-1-83
53.
Zurück zum Zitat Elnour AM, Elderdery AY, Mills J, Mohammed BA, ElbietAbdelaal D, Mohamed A, Elhassan K, Hady A, Wahab A, Cooper A (2012) BRCA 1 & 2 mutations in Sudanese secondary school girls with known breast cancer in their families. Int J Health Sci (Qassim) 6:8 Elnour AM, Elderdery AY, Mills J, Mohammed BA, ElbietAbdelaal D, Mohamed A, Elhassan K, Hady A, Wahab A, Cooper A (2012) BRCA 1 & 2 mutations in Sudanese secondary school girls with known breast cancer in their families. Int J Health Sci (Qassim) 6:8
54.
Zurück zum Zitat Olopade OI, Fackenthal JD, Dunston G, Tainsky MA, Collins F, Whitfield-Broome C (2003) Breast cancer genetics in African Americans. Cancer 97:236–245PubMedCrossRef Olopade OI, Fackenthal JD, Dunston G, Tainsky MA, Collins F, Whitfield-Broome C (2003) Breast cancer genetics in African Americans. Cancer 97:236–245PubMedCrossRef
55.
Zurück zum Zitat Stoppa-Lyonnet D, Laurent-Puig P, Essioux L, Pages S, Ithier G, Ligot L, Fourquet A, Salmon RJ, Clough KB, Pouillart P et al (1997) BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet 60:1021–1030PubMedPubMedCentral Stoppa-Lyonnet D, Laurent-Puig P, Essioux L, Pages S, Ithier G, Ligot L, Fourquet A, Salmon RJ, Clough KB, Pouillart P et al (1997) BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet 60:1021–1030PubMedPubMedCentral
56.
Zurück zum Zitat Lauby-Secretan B, Loomis D, Straif K (2015) Breast-cancer screening-viewpoint of the IARC Working Group. N Engl J Med 373:1479PubMed Lauby-Secretan B, Loomis D, Straif K (2015) Breast-cancer screening-viewpoint of the IARC Working Group. N Engl J Med 373:1479PubMed
57.
Zurück zum Zitat Laraqui A, Uhrhammer N, Rhaffouli HE, Sekhsokh Y, Lahlou-Amine I, Bajjou T, Hilali F, El Baghdadi J, Al Bouzidi A, Bakri Y et al (2015) BRCA genetic screening in Middle Eastern and North African: mutational spectrum and founder BRCA1 mutation (c.798_799delTT) in North African. Dis Markers. doi:10.1155/2015/194293 PubMedPubMedCentral Laraqui A, Uhrhammer N, Rhaffouli HE, Sekhsokh Y, Lahlou-Amine I, Bajjou T, Hilali F, El Baghdadi J, Al Bouzidi A, Bakri Y et al (2015) BRCA genetic screening in Middle Eastern and North African: mutational spectrum and founder BRCA1 mutation (c.798_799delTT) in North African. Dis Markers. doi:10.​1155/​2015/​194293 PubMedPubMedCentral
58.
Zurück zum Zitat Uhrhammer N, Abdelouahab A, Lafarge L, Feillel V, Ben Dib A, Bignon YJ (2008) BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases. Int J Med Sci 5:197–202PubMedPubMedCentralCrossRef Uhrhammer N, Abdelouahab A, Lafarge L, Feillel V, Ben Dib A, Bignon YJ (2008) BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases. Int J Med Sci 5:197–202PubMedPubMedCentralCrossRef
59.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386PubMedCrossRef Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386PubMedCrossRef
60.
Zurück zum Zitat Panieri E (2012) Breast cancer screening in developing countries. Best Pract Res Clin Obstet Gynaecol 26:283–290PubMedCrossRef Panieri E (2012) Breast cancer screening in developing countries. Best Pract Res Clin Obstet Gynaecol 26:283–290PubMedCrossRef
61.
Zurück zum Zitat Galukande M, Kiguli-Malwadde E (2010) Rethinking breast cancer screening strategies in resource-limited settings. Afr Health Sci 10:89–92PubMedPubMedCentral Galukande M, Kiguli-Malwadde E (2010) Rethinking breast cancer screening strategies in resource-limited settings. Afr Health Sci 10:89–92PubMedPubMedCentral
62.
Zurück zum Zitat Denewer A, Hussein O, Farouk O, Elnahas W, Khater A, El-Saed A (2010) Cost-effectiveness of clinical breast assessment-based screening in rural Egypt. World J Surg 34:2204–2210PubMedCrossRef Denewer A, Hussein O, Farouk O, Elnahas W, Khater A, El-Saed A (2010) Cost-effectiveness of clinical breast assessment-based screening in rural Egypt. World J Surg 34:2204–2210PubMedCrossRef
63.
Zurück zum Zitat Agodirin SO, Ojemakinde OM, Bello TO, Oguntola AS, Aremu AA, Ojemakinde KO, Adeoti ML, Agbakwuru EA (2012) Ultrasound-guided wire localization of lesions detected on screening mammography in Osogbo, Nigeria and its impact on breast conservative surgery. Ann Afr Med 11:91–95PubMedCrossRef Agodirin SO, Ojemakinde OM, Bello TO, Oguntola AS, Aremu AA, Ojemakinde KO, Adeoti ML, Agbakwuru EA (2012) Ultrasound-guided wire localization of lesions detected on screening mammography in Osogbo, Nigeria and its impact on breast conservative surgery. Ann Afr Med 11:91–95PubMedCrossRef
64.
Zurück zum Zitat Koon KP, Lehman CD, Gralow JR (2013) The importance of survivors and partners in improving breast cancer outcomes in Uganda. Breast 22:138–141PubMedCrossRef Koon KP, Lehman CD, Gralow JR (2013) The importance of survivors and partners in improving breast cancer outcomes in Uganda. Breast 22:138–141PubMedCrossRef
65.
Zurück zum Zitat Batsis C (2011) Two-stage breast cancer screening in the developing world. World J Surg 35:698–699PubMedCrossRef Batsis C (2011) Two-stage breast cancer screening in the developing world. World J Surg 35:698–699PubMedCrossRef
66.
Zurück zum Zitat Gutnik L, Lee C, Msosa V, Moses A, Stanley C, Mzumara S, Liomba NG, Gopal S (2016) Clinical breast examination screening by trained laywomen in Malawi integrated with other health services. J Surg Res 204:61–67PubMedPubMedCentralCrossRef Gutnik L, Lee C, Msosa V, Moses A, Stanley C, Mzumara S, Liomba NG, Gopal S (2016) Clinical breast examination screening by trained laywomen in Malawi integrated with other health services. J Surg Res 204:61–67PubMedPubMedCentralCrossRef
67.
Zurück zum Zitat El Fakir S, Najdi A, Khazraji YC, Bennani M, Belakhel L, Abousselham L, Lyoussi B, Bekkali R, Nejjari C (2015) Breast cancer screening in Morocco: performance indicators during two years of an organized programme. Asian Pac J Cancer Prev 16:6285–6288PubMedCrossRef El Fakir S, Najdi A, Khazraji YC, Bennani M, Belakhel L, Abousselham L, Lyoussi B, Bekkali R, Nejjari C (2015) Breast cancer screening in Morocco: performance indicators during two years of an organized programme. Asian Pac J Cancer Prev 16:6285–6288PubMedCrossRef
68.
Zurück zum Zitat Suh MA, Atashili J, Fuh EA, Eta VA (2012) Breast self-examination and breast cancer awareness in women in developing countries: a survey of women in Buea, Cameroon. BMC Res Notes 5:627PubMedPubMedCentralCrossRef Suh MA, Atashili J, Fuh EA, Eta VA (2012) Breast self-examination and breast cancer awareness in women in developing countries: a survey of women in Buea, Cameroon. BMC Res Notes 5:627PubMedPubMedCentralCrossRef
69.
Zurück zum Zitat Pengpid S, Peltzer K (2014) Knowledge, attitude and practice of breast self-examination among female university students from 24 low, middle income and emerging economy countries. Asian Pac J Cancer Prev 15:8637–8640PubMedCrossRef Pengpid S, Peltzer K (2014) Knowledge, attitude and practice of breast self-examination among female university students from 24 low, middle income and emerging economy countries. Asian Pac J Cancer Prev 15:8637–8640PubMedCrossRef
70.
Zurück zum Zitat Oladimeji KE, Tsoka-Gwegweni JM, Igbodekwe FC, Twomey M, Akolo C, Balarabe HS, Atilola O, Jegede O, Oladimeji O (2015) Knowledge and beliefs of breast self-examination and breast cancer among market women in Ibadan, South West, Nigeria. PLoS ONE 10:e0140904PubMedPubMedCentralCrossRef Oladimeji KE, Tsoka-Gwegweni JM, Igbodekwe FC, Twomey M, Akolo C, Balarabe HS, Atilola O, Jegede O, Oladimeji O (2015) Knowledge and beliefs of breast self-examination and breast cancer among market women in Ibadan, South West, Nigeria. PLoS ONE 10:e0140904PubMedPubMedCentralCrossRef
72.
Zurück zum Zitat Plouffe L Jr (2000) Selective estrogen receptor modulators (SERMs) in clinical practice. J Soc Gynecol Investig 7:S38–S46PubMedCrossRef Plouffe L Jr (2000) Selective estrogen receptor modulators (SERMs) in clinical practice. J Soc Gynecol Investig 7:S38–S46PubMedCrossRef
73.
74.
Zurück zum Zitat Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273–1283PubMedPubMedCentralCrossRef Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273–1283PubMedPubMedCentralCrossRef
75.
Zurück zum Zitat Singh JC, Jhaveri K, Esteva FJ (2014) HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. Br J Cancer 111:1888–1898PubMedPubMedCentralCrossRef Singh JC, Jhaveri K, Esteva FJ (2014) HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. Br J Cancer 111:1888–1898PubMedPubMedCentralCrossRef
76.
Zurück zum Zitat Dieras V, Vincent-Salomon A, Degeorges A, Beuzeboc P, Mignot L, de Cremoux P (2007) Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance. Bull Cancer 94:259–266PubMed Dieras V, Vincent-Salomon A, Degeorges A, Beuzeboc P, Mignot L, de Cremoux P (2007) Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance. Bull Cancer 94:259–266PubMed
77.
Zurück zum Zitat Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX (2010) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. doi:10.1007/s10549-010-1090-x PubMed Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX (2010) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. doi:10.​1007/​s10549-010-1090-x PubMed
78.
Zurück zum Zitat Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE, Martino S, Mamounas EP, Kaufman PA, Wolmark N (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366–3373PubMedPubMedCentralCrossRef Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE, Martino S, Mamounas EP, Kaufman PA, Wolmark N (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366–3373PubMedPubMedCentralCrossRef
80.
Zurück zum Zitat Langenhoven L, Barnardt P, Jacobson J (2016) Phenotype and treatment of breast cancer in HIV-positive and -negative women in Cape Town, South Africa. J Glob Oncol 2:284–291PubMedPubMedCentralCrossRef Langenhoven L, Barnardt P, Jacobson J (2016) Phenotype and treatment of breast cancer in HIV-positive and -negative women in Cape Town, South Africa. J Glob Oncol 2:284–291PubMedPubMedCentralCrossRef
81.
Zurück zum Zitat Islami F, Lortet-Tieulent J, Okello C, Adoubi I, Mbalawa CG, Ward EM, Parkin DM, Jemal A (2015) Tumor size and stage of breast cancer in Cote d’Ivoire and Republic of Congo—results from population-based cancer registries. Breast 24:713–717PubMedCrossRef Islami F, Lortet-Tieulent J, Okello C, Adoubi I, Mbalawa CG, Ward EM, Parkin DM, Jemal A (2015) Tumor size and stage of breast cancer in Cote d’Ivoire and Republic of Congo—results from population-based cancer registries. Breast 24:713–717PubMedCrossRef
83.
Zurück zum Zitat Bhikoo R, Srinivasa S, Yu TC, Moss D, Hill AG (2011) Systematic review of breast cancer biology in developing countries (part 2): Asian subcontinent and South East Asia. Cancers (Basel) 3:2382–2401CrossRef Bhikoo R, Srinivasa S, Yu TC, Moss D, Hill AG (2011) Systematic review of breast cancer biology in developing countries (part 2): Asian subcontinent and South East Asia. Cancers (Basel) 3:2382–2401CrossRef
84.
Zurück zum Zitat Maalej M, Frikha H, Ben Salem S, Daoud J, Bouaouina N, Ben Abdallah M, Ben Romdhane K (1999) Breast cancer in Tunisia: clinical and epidemiological study. Bull Cancer 86:302–306PubMed Maalej M, Frikha H, Ben Salem S, Daoud J, Bouaouina N, Ben Abdallah M, Ben Romdhane K (1999) Breast cancer in Tunisia: clinical and epidemiological study. Bull Cancer 86:302–306PubMed
85.
Zurück zum Zitat Maalej M, Hentati D, Messai T, Kochbati L, El May A, Mrad K, Romdhane KB, Ben Abdallah M, Zouari B (2008) Breast cancer in Tunisia in 2004: a comparative clinical and epidemiological study. Bull Cancer 95:E5–E9PubMed Maalej M, Hentati D, Messai T, Kochbati L, El May A, Mrad K, Romdhane KB, Ben Abdallah M, Zouari B (2008) Breast cancer in Tunisia in 2004: a comparative clinical and epidemiological study. Bull Cancer 95:E5–E9PubMed
86.
Zurück zum Zitat Price AJ, Ndom P, Atenguena E, Mambou Nouemssi JP, Ryder RW (2012) Cancer care challenges in developing countries. Cancer 118:3627–3635PubMedCrossRef Price AJ, Ndom P, Atenguena E, Mambou Nouemssi JP, Ryder RW (2012) Cancer care challenges in developing countries. Cancer 118:3627–3635PubMedCrossRef
87.
Zurück zum Zitat Jakesz R (2008) Breast cancer in developing countries: challenges for multidisciplinary care. Breast Care (Basel) 3:4–5CrossRef Jakesz R (2008) Breast cancer in developing countries: challenges for multidisciplinary care. Breast Care (Basel) 3:4–5CrossRef
88.
89.
Zurück zum Zitat Adisa AO, Gukas ID, Lawal OO, Adesunkanmi ARK (2010) Breast cancer in Nigeria: is non-adherence to chemotherapy schedules a major factor in the reported poor treatment outcome? Breast J 16:206–207PubMedCrossRef Adisa AO, Gukas ID, Lawal OO, Adesunkanmi ARK (2010) Breast cancer in Nigeria: is non-adherence to chemotherapy schedules a major factor in the reported poor treatment outcome? Breast J 16:206–207PubMedCrossRef
90.
Zurück zum Zitat ’t Hoen E (2013) A victory for global public health in the Indian Supreme Court. J Public Health Policy 34:370–374PubMedCrossRef ’t Hoen E (2013) A victory for global public health in the Indian Supreme Court. J Public Health Policy 34:370–374PubMedCrossRef
91.
Zurück zum Zitat Hanlon M, Zhang R (2013) Price discrimination in essential medicines: evidence from International Drug Price Indicator Guide data. Int Health 5:58–63PubMedCrossRef Hanlon M, Zhang R (2013) Price discrimination in essential medicines: evidence from International Drug Price Indicator Guide data. Int Health 5:58–63PubMedCrossRef
92.
Zurück zum Zitat Knaul F, Frenk J, Shulman L (2011) Closing the cancer divide: a blueprint to expand access in low and middle income countries. President and Fellows of Harvard College Knaul F, Frenk J, Shulman L (2011) Closing the cancer divide: a blueprint to expand access in low and middle income countries. President and Fellows of Harvard College
93.
Zurück zum Zitat Mayor S (2015) WHO includes 16 new cancer drugs on list of essential medicines. Lancet Oncol 16:757PubMedCrossRef Mayor S (2015) WHO includes 16 new cancer drugs on list of essential medicines. Lancet Oncol 16:757PubMedCrossRef
94.
Zurück zum Zitat Aitelhaj M, Lkhoyaali S, Rais G, Boutayeb S, Errihani H (2016) First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive—observational institutional study. Pan Afr Med J 24:324PubMedPubMedCentralCrossRef Aitelhaj M, Lkhoyaali S, Rais G, Boutayeb S, Errihani H (2016) First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive—observational institutional study. Pan Afr Med J 24:324PubMedPubMedCentralCrossRef
95.
Zurück zum Zitat ‘t Hoen E (2015) A study of medicine pricing issues with recommendations for improving access to cancer medication. OXFAM: ACCESS TO CANCER TREATMENT, p 54 ‘t Hoen E (2015) A study of medicine pricing issues with recommendations for improving access to cancer medication. OXFAM: ACCESS TO CANCER TREATMENT, p 54
96.
Zurück zum Zitat Zhang G, Wang Y, Zhang Y, Wan X, Li J, Liu K, Wang F, Liu K, Liu Q, Yang C et al (2012) Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy. Curr Mol Med 12:163–176PubMedPubMedCentralCrossRef Zhang G, Wang Y, Zhang Y, Wan X, Li J, Liu K, Wang F, Liu K, Liu Q, Yang C et al (2012) Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy. Curr Mol Med 12:163–176PubMedPubMedCentralCrossRef
97.
Zurück zum Zitat Huang J, Yang B, Xiang T, Peng W, Qiu Z, Wan J, Zhang L, Li H, Li H, Ren G (2015) Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the beta-catenin signaling pathway. Mol Nutr Food Res 59:1063–1075PubMedCrossRef Huang J, Yang B, Xiang T, Peng W, Qiu Z, Wan J, Zhang L, Li H, Li H, Ren G (2015) Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the beta-catenin signaling pathway. Mol Nutr Food Res 59:1063–1075PubMedCrossRef
98.
Zurück zum Zitat Abu Sayeed M, Bracci M, Lazzarini R, Tomasetti M, Amati M, Lucarini G, Di Primio R, Santarelli L (2017) Use of potential dietary phytochemicals to target miRNA: promising option for breast cancer prevention and treatment? J Funct Foods 28:177–193CrossRef Abu Sayeed M, Bracci M, Lazzarini R, Tomasetti M, Amati M, Lucarini G, Di Primio R, Santarelli L (2017) Use of potential dietary phytochemicals to target miRNA: promising option for breast cancer prevention and treatment? J Funct Foods 28:177–193CrossRef
99.
Zurück zum Zitat Kim SH, Singh SV (2015) The role of polycomb group protein Bmi-1 and Notch4 in breast cancer stem cell inhibition by benzyl isothiocyanate. Breast Cancer Res Treat 149:681–692PubMedPubMedCentralCrossRef Kim SH, Singh SV (2015) The role of polycomb group protein Bmi-1 and Notch4 in breast cancer stem cell inhibition by benzyl isothiocyanate. Breast Cancer Res Treat 149:681–692PubMedPubMedCentralCrossRef
100.
Zurück zum Zitat Farzaei MH, Bahramsoltani R, Rahimi R (2016) Phytochemicals as adjunctive with conventional anticancer therapies. Curr Pharm Des 22:4201–4218PubMedCrossRef Farzaei MH, Bahramsoltani R, Rahimi R (2016) Phytochemicals as adjunctive with conventional anticancer therapies. Curr Pharm Des 22:4201–4218PubMedCrossRef
101.
Zurück zum Zitat Fouche G, Cragg GM, Pillay P, Kolesnikova N, Maharaj VJ, Senabe J (2008) In vitro anticancer screening of South African plants. J Ethnopharmacol 119:455–461PubMedCrossRef Fouche G, Cragg GM, Pillay P, Kolesnikova N, Maharaj VJ, Senabe J (2008) In vitro anticancer screening of South African plants. J Ethnopharmacol 119:455–461PubMedCrossRef
102.
Zurück zum Zitat Ochwang’i DO, Kimwele CN, Oduma JA, Gathumbi PK, Mbaria JM, Kiama SG (2014) Medicinal plants used in treatment and management of cancer in Kakamega County, Kenya. J Ethnopharmacol 151:1040–1055PubMedCrossRef Ochwang’i DO, Kimwele CN, Oduma JA, Gathumbi PK, Mbaria JM, Kiama SG (2014) Medicinal plants used in treatment and management of cancer in Kakamega County, Kenya. J Ethnopharmacol 151:1040–1055PubMedCrossRef
103.
Zurück zum Zitat Hadi SM, Asad SF, Singh S, Ahmad A (2000) Putative mechanism for anticancer and apoptosis-inducing properties of plant-derived polyphenolic compounds. IUBMB Life 50:167–171PubMedCrossRef Hadi SM, Asad SF, Singh S, Ahmad A (2000) Putative mechanism for anticancer and apoptosis-inducing properties of plant-derived polyphenolic compounds. IUBMB Life 50:167–171PubMedCrossRef
104.
Zurück zum Zitat Orhan IE, Kartal M, Gulpinar AR, Cos P, Matheeussen A, Maes L, Tasdemir D (2013) Assessment of antimicrobial and antiprotozoal activity of the olive oil macerate samples of Hypericum perforatum and their LC-DAD-MS analyses. Food Chem 138:870–875PubMedCrossRef Orhan IE, Kartal M, Gulpinar AR, Cos P, Matheeussen A, Maes L, Tasdemir D (2013) Assessment of antimicrobial and antiprotozoal activity of the olive oil macerate samples of Hypericum perforatum and their LC-DAD-MS analyses. Food Chem 138:870–875PubMedCrossRef
105.
Zurück zum Zitat Bachmeier B, Nerlich AG, Iancu CM, Cilli M, Schleicher E, Vene R, Dell’Eva R, Jochum M, Albini A, Pfeffer U (2007) The chemopreventive polyphenol curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell Physiol Biochem 19:137–152PubMedCrossRef Bachmeier B, Nerlich AG, Iancu CM, Cilli M, Schleicher E, Vene R, Dell’Eva R, Jochum M, Albini A, Pfeffer U (2007) The chemopreventive polyphenol curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell Physiol Biochem 19:137–152PubMedCrossRef
106.
Zurück zum Zitat Weng CJ, Yen GC (2012) Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: phenolic acids, monophenol, polyphenol, and their derivatives. Cancer Treat Rev 38:76–87PubMedCrossRef Weng CJ, Yen GC (2012) Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: phenolic acids, monophenol, polyphenol, and their derivatives. Cancer Treat Rev 38:76–87PubMedCrossRef
107.
Zurück zum Zitat Nwodo JN, Ibezim A, Simoben CV, Ntie-Kang F (2016) Exploring cancer therapeutics with natural products from African medicinal plants, Part II: alkaloids, terpenoids and flavonoids. Anticancer Agents Med Chem 16:108–127PubMedCrossRef Nwodo JN, Ibezim A, Simoben CV, Ntie-Kang F (2016) Exploring cancer therapeutics with natural products from African medicinal plants, Part II: alkaloids, terpenoids and flavonoids. Anticancer Agents Med Chem 16:108–127PubMedCrossRef
108.
Zurück zum Zitat Li X, Yang GY, Li XX, Zhang Y, Yang JL, Chang J, Sun XX, Zhou XY, Guo Y, Xu Y et al (2013) Traditional Chinese medicine in cancer care: a review of controlled clinical studies published in Chinese. PLoS ONE. doi:10.1371/journal.pone.0060338 Li X, Yang GY, Li XX, Zhang Y, Yang JL, Chang J, Sun XX, Zhou XY, Guo Y, Xu Y et al (2013) Traditional Chinese medicine in cancer care: a review of controlled clinical studies published in Chinese. PLoS ONE. doi:10.​1371/​journal.​pone.​0060338
109.
Zurück zum Zitat Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J, Lin HS (2004) Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 24:303–309PubMed Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J, Lin HS (2004) Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 24:303–309PubMed
110.
Zurück zum Zitat Büssing A (2000) Mistletoe: the genus Viscum. Medicinal and aromatic plants—industrial profiles, p 280 Büssing A (2000) Mistletoe: the genus Viscum. Medicinal and aromatic plants—industrial profiles, p 280
111.
Zurück zum Zitat Dai Z, Wan X, Kang H, Ji Z, Liu L, Liu X, Song L, Min W, Ma X (2008) Clinical effects of Shenqi Fuzheng injection in the neoadjuvant chemotherapy for local advanced breast cancer and the effects on T-lymphocyte subsets. J Tradit Chin Med 28:34–38PubMedCrossRef Dai Z, Wan X, Kang H, Ji Z, Liu L, Liu X, Song L, Min W, Ma X (2008) Clinical effects of Shenqi Fuzheng injection in the neoadjuvant chemotherapy for local advanced breast cancer and the effects on T-lymphocyte subsets. J Tradit Chin Med 28:34–38PubMedCrossRef
112.
Zurück zum Zitat Dong J, Su SY, Wang MY, Zhan Z (2010) Shenqi Fuzheng, an injection concocted from Chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review. J Exp Clin Cancer Res 29:137PubMedPubMedCentralCrossRef Dong J, Su SY, Wang MY, Zhan Z (2010) Shenqi Fuzheng, an injection concocted from Chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review. J Exp Clin Cancer Res 29:137PubMedPubMedCentralCrossRef
113.
Zurück zum Zitat Dedong C, Huilin X, Anbing H, Ximing X, Wei G (2016) The effect of ShenQi FuZheng injection in combination with chemotherapy versus chemotherapy alone on the improvement of efficacy and immune function in patients with advanced non-small cell lung cancer: a meta-analysis. PLoS ONE 11:e0152270PubMedPubMedCentralCrossRef Dedong C, Huilin X, Anbing H, Ximing X, Wei G (2016) The effect of ShenQi FuZheng injection in combination with chemotherapy versus chemotherapy alone on the improvement of efficacy and immune function in patients with advanced non-small cell lung cancer: a meta-analysis. PLoS ONE 11:e0152270PubMedPubMedCentralCrossRef
114.
Zurück zum Zitat Huang ZF, Wei JS, Li HZ (2008) Effect of Shenqi Fuzheng injection combined with chemotherapy on thirty patients with advanced breast cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi 28:152–154PubMed Huang ZF, Wei JS, Li HZ (2008) Effect of Shenqi Fuzheng injection combined with chemotherapy on thirty patients with advanced breast cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi 28:152–154PubMed
115.
Zurück zum Zitat Li HS, Yang B, Su XC (2009) Effect of Shenqi Fuzheng injection on repairing the immune function in patients with breast cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi 29:537–539PubMed Li HS, Yang B, Su XC (2009) Effect of Shenqi Fuzheng injection on repairing the immune function in patients with breast cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi 29:537–539PubMed
116.
Zurück zum Zitat Lv Y, Zhang G, Ma Y, Ma M, Liao R, Xiang J, Chen R, Yan X, Bie F, Huang M et al (2015) Shenqi Fuzheng injection combined with chemotherapy for breast cancer: a meta-analysis of randomized controlled trials. Evid Based Complement Altern Med 2015:635858 Lv Y, Zhang G, Ma Y, Ma M, Liao R, Xiang J, Chen R, Yan X, Bie F, Huang M et al (2015) Shenqi Fuzheng injection combined with chemotherapy for breast cancer: a meta-analysis of randomized controlled trials. Evid Based Complement Altern Med 2015:635858
117.
Zurück zum Zitat Wong CK, Bao YX, Wong ELY, Leung PC, Fung KP, Lam CWK (2005) Immunomodulatory activities of Yunzhi and Danshen in post-treatment breast cancer patients. Am J Chin Med 33:381–395PubMedCrossRef Wong CK, Bao YX, Wong ELY, Leung PC, Fung KP, Lam CWK (2005) Immunomodulatory activities of Yunzhi and Danshen in post-treatment breast cancer patients. Am J Chin Med 33:381–395PubMedCrossRef
118.
Zurück zum Zitat Kladar NV, Gavaric NS, Bozin BN (2016) Ganoderma: insights into anticancer effects. Eur J Cancer Prev 25:462–471PubMedCrossRef Kladar NV, Gavaric NS, Bozin BN (2016) Ganoderma: insights into anticancer effects. Eur J Cancer Prev 25:462–471PubMedCrossRef
119.
Zurück zum Zitat Shin A, Kim J, Lim SY, Kim G, Sung MK, Lee ES, Ro J (2010) Dietary mushroom intake and the risk of breast cancer based on hormone receptor status. Nutr Cancer Int J 62:476–483CrossRef Shin A, Kim J, Lim SY, Kim G, Sung MK, Lee ES, Ro J (2010) Dietary mushroom intake and the risk of breast cancer based on hormone receptor status. Nutr Cancer Int J 62:476–483CrossRef
120.
Zurück zum Zitat Bao PP, Lu W, Cui Y, Zheng Y, Gu K, Chen Z, Zheng W, Shu XO (2012) Ginseng and Ganoderma lucidum use after breast cancer diagnosis and quality of life: a report from the Shanghai Breast Cancer Survival Study. PLoS ONE 7:e39343PubMedPubMedCentralCrossRef Bao PP, Lu W, Cui Y, Zheng Y, Gu K, Chen Z, Zheng W, Shu XO (2012) Ginseng and Ganoderma lucidum use after breast cancer diagnosis and quality of life: a report from the Shanghai Breast Cancer Survival Study. PLoS ONE 7:e39343PubMedPubMedCentralCrossRef
121.
Zurück zum Zitat Barbieri A, Quagliariello V, Del Vecchio V, Falco M, Luciano A, Amruthraj NJ, Nasti G, Ottaiano A, Berretta M, Iaffaioli RV et al (2017) Anticancer and anti-inflammatory properties of Ganoderma lucidum extract effects on melanoma and triple-negative breast cancer treatment. Nutrients. doi:10.3390/nu9030210 Barbieri A, Quagliariello V, Del Vecchio V, Falco M, Luciano A, Amruthraj NJ, Nasti G, Ottaiano A, Berretta M, Iaffaioli RV et al (2017) Anticancer and anti-inflammatory properties of Ganoderma lucidum extract effects on melanoma and triple-negative breast cancer treatment. Nutrients. doi:10.​3390/​nu9030210
122.
Zurück zum Zitat Gonul O, Aydin HH, Kalmis E, Kayalar H, Ozkaya AB, Atay S, Ak H (2015) Effects of Ganoderma lucidum (higher Basidiomycetes) extracts on the miRNA profile and telomerase activity of the MCF-7 breast cancer cell line. Int J Med Mushrooms 17:231–239PubMedCrossRef Gonul O, Aydin HH, Kalmis E, Kayalar H, Ozkaya AB, Atay S, Ak H (2015) Effects of Ganoderma lucidum (higher Basidiomycetes) extracts on the miRNA profile and telomerase activity of the MCF-7 breast cancer cell line. Int J Med Mushrooms 17:231–239PubMedCrossRef
123.
Zurück zum Zitat Hu H, Ahn NS, Yang X, Lee YS, Kang KS (2002) Ganoderma lucidum extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. Int J Cancer 102:250–253PubMedCrossRef Hu H, Ahn NS, Yang X, Lee YS, Kang KS (2002) Ganoderma lucidum extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. Int J Cancer 102:250–253PubMedCrossRef
124.
Zurück zum Zitat Jiang J, Slivova V, Harvey K, Valachovicova T, Sliva D (2004) Ganoderma lucidum suppresses growth of breast cancer cells through the inhibition of Akt/NF-kappaB signaling. Nutr Cancer 49:209–216PubMedCrossRef Jiang J, Slivova V, Harvey K, Valachovicova T, Sliva D (2004) Ganoderma lucidum suppresses growth of breast cancer cells through the inhibition of Akt/NF-kappaB signaling. Nutr Cancer 49:209–216PubMedCrossRef
125.
Zurück zum Zitat Jiang J, Slivova V, Sliva D (2006) Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling. Int J Oncol 29:695–703PubMed Jiang J, Slivova V, Sliva D (2006) Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling. Int J Oncol 29:695–703PubMed
126.
Zurück zum Zitat Kim TH, Kim JS, Kim ZH, Huang RB, Chae YL, Wang RS (2016) Induction of apoptosis in MCF7 human breast cancer cells by Khz (fusion of Ganoderma lucidum and Polyporus umbellatus mycelium). Mol Med Rep 13:1243–1249PubMedCrossRef Kim TH, Kim JS, Kim ZH, Huang RB, Chae YL, Wang RS (2016) Induction of apoptosis in MCF7 human breast cancer cells by Khz (fusion of Ganoderma lucidum and Polyporus umbellatus mycelium). Mol Med Rep 13:1243–1249PubMedCrossRef
127.
Zurück zum Zitat Loganathan J, Jiang J, Smith A, Jedinak A, Thyagarajan-Sahu A, Sandusky GE, Nakshatri H, Sliva D (2014) The mushroom Ganoderma lucidum suppresses breast-to-lung cancer metastasis through the inhibition of pro-invasive genes. Int J Oncol 44:2009–2015PubMedPubMedCentralCrossRef Loganathan J, Jiang J, Smith A, Jedinak A, Thyagarajan-Sahu A, Sandusky GE, Nakshatri H, Sliva D (2014) The mushroom Ganoderma lucidum suppresses breast-to-lung cancer metastasis through the inhibition of pro-invasive genes. Int J Oncol 44:2009–2015PubMedPubMedCentralCrossRef
128.
Zurück zum Zitat Lu QY, Sartippour MR, Brooks MN, Zhang Q, Hardy M, Go VL, Li FP, Heber D (2004) Ganoderma lucidum spore extract inhibits endothelial and breast cancer cells in vitro. Oncol Rep 12:659–662PubMed Lu QY, Sartippour MR, Brooks MN, Zhang Q, Hardy M, Go VL, Li FP, Heber D (2004) Ganoderma lucidum spore extract inhibits endothelial and breast cancer cells in vitro. Oncol Rep 12:659–662PubMed
129.
Zurück zum Zitat Martinez-Montemayor MM, Acevedo RR, Otero-Franqui E, Cubano LA, Dharmawardhane SF (2011) Ganoderma lucidum (Reishi) inhibits cancer cell growth and expression of key molecules in inflammatory breast cancer. Nutr Cancer 63:1085–1094PubMedPubMedCentralCrossRef Martinez-Montemayor MM, Acevedo RR, Otero-Franqui E, Cubano LA, Dharmawardhane SF (2011) Ganoderma lucidum (Reishi) inhibits cancer cell growth and expression of key molecules in inflammatory breast cancer. Nutr Cancer 63:1085–1094PubMedPubMedCentralCrossRef
130.
Zurück zum Zitat Shang D, Li Y, Wang C, Wang X, Yu Z, Fu X (2011) A novel polysaccharide from Se-enriched Ganoderma lucidum induces apoptosis of human breast cancer cells. Oncol Rep 25:267–272PubMed Shang D, Li Y, Wang C, Wang X, Yu Z, Fu X (2011) A novel polysaccharide from Se-enriched Ganoderma lucidum induces apoptosis of human breast cancer cells. Oncol Rep 25:267–272PubMed
131.
Zurück zum Zitat Sliva D, Labarrere C, Slivova V, Sedlak M, Lloyd FP Jr, Ho NW (2002) Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells. Biochem Biophys Res Commun 298:603–612PubMedCrossRef Sliva D, Labarrere C, Slivova V, Sedlak M, Lloyd FP Jr, Ho NW (2002) Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells. Biochem Biophys Res Commun 298:603–612PubMedCrossRef
132.
Zurück zum Zitat Sliva D, Sedlak M, Slivova V, Valachovicova T, Lloyd FP Jr, Ho NW (2003) Biologic activity of spores and dried powder from Ganoderma lucidum for the inhibition of highly invasive human breast and prostate cancer cells. J Altern Complement Med 9:491–497PubMedCrossRef Sliva D, Sedlak M, Slivova V, Valachovicova T, Lloyd FP Jr, Ho NW (2003) Biologic activity of spores and dried powder from Ganoderma lucidum for the inhibition of highly invasive human breast and prostate cancer cells. J Altern Complement Med 9:491–497PubMedCrossRef
133.
Zurück zum Zitat Zhang M, Huang J, Xie X, Holman CDJ (2009) Dietary intakes of mushrooms and green tea combine to reduce the risk of breast cancer in Chinese women. Int J Cancer 124:1404–1408PubMedCrossRef Zhang M, Huang J, Xie X, Holman CDJ (2009) Dietary intakes of mushrooms and green tea combine to reduce the risk of breast cancer in Chinese women. Int J Cancer 124:1404–1408PubMedCrossRef
134.
Zurück zum Zitat Chen Z, Gu K, Zheng Y, Zheng W, Lu W, Shu XO (2008) The use of complementary and alternative medicine among Chinese women with breast cancer. J Altern Complement Med 14:1049–1055PubMedCrossRef Chen Z, Gu K, Zheng Y, Zheng W, Lu W, Shu XO (2008) The use of complementary and alternative medicine among Chinese women with breast cancer. J Altern Complement Med 14:1049–1055PubMedCrossRef
135.
Zurück zum Zitat Tian HQ, Wang YJ, Wang B, Huang YL, Li HL, Huang XQ, Zhang XC, Yang YL (2013) Effect of ruji recipe on the post-surgical survival of female breast cancer patients. Zhongguo Zhong Xi Yi Jie He Za Zhi 33:1336–1340PubMed Tian HQ, Wang YJ, Wang B, Huang YL, Li HL, Huang XQ, Zhang XC, Yang YL (2013) Effect of ruji recipe on the post-surgical survival of female breast cancer patients. Zhongguo Zhong Xi Yi Jie He Za Zhi 33:1336–1340PubMed
137.
Zurück zum Zitat Sylla BS, Wild CP (2012) A million Africans a year dying from cancer by 2030: what can cancer research and control offer to the continent? Int J Cancer 130:245–250PubMedCrossRef Sylla BS, Wild CP (2012) A million Africans a year dying from cancer by 2030: what can cancer research and control offer to the continent? Int J Cancer 130:245–250PubMedCrossRef
138.
Zurück zum Zitat Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236PubMedCrossRef Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236PubMedCrossRef
139.
Zurück zum Zitat Phillips C, Jeffree R, Khasraw M (2017) Management of breast cancer brain metastases: a practical review. Breast 31:90–98PubMedCrossRef Phillips C, Jeffree R, Khasraw M (2017) Management of breast cancer brain metastases: a practical review. Breast 31:90–98PubMedCrossRef
Metadaten
Titel
Breast cancer in Africa: prevalence, treatment options, herbal medicines, and socioeconomic determinants
verfasst von
Kiven Erique Lukong
Yetunde Ogunbolude
Jean Paul Kamdem
Publikationsdatum
04.08.2017
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4408-0

Weitere Artikel der Ausgabe 2/2017

Breast Cancer Research and Treatment 2/2017 Zur Ausgabe

Letter to the Editor

Reply to Kopans

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.